Company Encyclopedia
View More
name
SPDR S&P Em S-Cap
EWX.US
News
View More

SG Americas Securities LLC Makes New $399,000 Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR

SG Americas Securities LLC invested $399,000 in Structure Therapeutics Inc. during Q2, acquiring 19,239 shares. Other institutional investors also adjusted their positions. Analysts have mixed ratings, with a consensus target price of $68.67. Structure Therapeutics' stock opened at $34.22, with a market cap of $1.98 billion. The company focuses on developing oral therapeutics for chronic diseases.

Market Beat·
US
GPCR
+3.89%
Market Beat·
US
GPCR
+3.89%

Promising Potential of Structure Therapeutics’ Aleniglipron in the Incretin-Based Therapy Landscape

Ananda Ghosh from H.C. Wainwright maintains a Buy rating on Structure Therapeutics with a $60 target, citing the potential of aleniglipron, an oral GLP-1 therapy, to fill gaps in incretin-based therapies. The Phase 2b ACCESS studies aim for 10-12% weight loss with better tolerability. Success could lead to Phase 3 trials and a 25-30% stock upside. Jefferies also maintains a Buy rating with a $79 target.

Tip Ranks·
US
GPCR
+3.89%
Tip Ranks·
US
GPCR
+3.89%

Buy Rating for Structure Therapeutics, Inc.: Potential Disruption in Obesity Treatment with Amylin Agonists

Wall Street analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on Structure Therapeutics, Inc. with a $72.00 price target, citing the potential of their small molecule amylin agonists in obesity treatment. The company's lead candidate, ACCG-2671, is set for trials by 2025, with promising efficacy in weight loss. BMO Capital also reiterated a Buy rating with a $100.00 target, highlighting the company's potential to disrupt the obesity treatment market.

Tip Ranks·
US
GPCR
+3.89%
Tip Ranks·
US
GPCR
+3.89%

Buy Rating on Structure Therapeutics, Inc. Driven by Aleniglipron’s Potential in the Obesity Market

Evan Seigerman from BMO Capital reiterated a Buy rating on Structure Therapeutics, Inc. with a $100 price target, driven by the potential of its oral GLP-1 receptor agonist, aleniglipron, in the obesity market. The ACCESS trials are expected to show significant weight loss efficacy. Despite short-term pricing pressures, the long-term growth potential remains strong. Cantor Fitzgerald also maintained a Buy rating with a $65 target.

Tip Ranks·
US
GPCR
+3.89%
Tip Ranks·
US
GPCR
+3.89%

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.7% - Here's What Happened

Structure Therapeutics (NASDAQ:GPCR) shares fell 6.7% to $34.9410, with trading volume up 45% from the average. Analysts have mixed ratings: Guggenheim and HC Wainwright lowered target prices but maintained 'buy' ratings, while Weiss Ratings issued a 'sell' rating. The company reported a Q3 EPS of ($0.37), missing estimates. Institutional investors hold 91.78% of shares. Structure Therapeutics develops oral therapeutics for chronic diseases, with GSBR-1290 as a lead candidate for diabetes and obesity.

Market Beat·
US
GPCR
+3.89%
Market Beat·
US
GPCR
+3.89%
© 2025 Longbridge｜Disclaimer